TMCnet News
T2 Biosystems Invites Attendees of the American Society for Microbiology General Meeting to Events Featuring the Company's Flagship Diagnostic Test - T2Candida®LEXINGTON, Mass. --(Business Wire)-- T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced details of its participation at the upcoming American Society for Microbiology General Meeting being held May 18-21, 2013, in Denver, CO. T2 Bio will provide two opportunities to learn about its core T2MR® technology, as well as T2Candida, its rapid and sensitive flagship assay that is capable of identifying five Candida species directly from whole blood in approximately 3 hours with a limit of detection as low as 1 CFU/mL. T2 Biosystems will host a symposium entitled "T2MR direct detection of Candida in whole blood: rapid, species-specific identification of Candida infections". The symposium will take place on May 19, 2013, and feature distinguished speakers Peter Pappas, MD, Principal Investigator, Mycoses Study Group and Professor, University of Alabama, Birmingham and Michael Pfaller, MD, Professor Emeritus, University of Iowa. In addition, T2 Biosystems will provide demonstrations of the T2Candida diagnostic test on the T2Dx instrument throughout exhibit hall hours at booth #732. Dr. Pfaller will present the diagnostic and therapeutic landscape of candidemia, the fourth-leading cause of hospital-acquired infections. Candidemia currently has a 40% mortality rate, largely due to the delay in diagnosis, whch can take two to five days with the current gold standard of blood culture. Dr. Pappas will introduce T2Candida®, T2 Bio's flagship diagnostic test, as a means to rapidly and accurately identify species-specific Candida directly from whole blood in approximately three hours, which is up to 25X faster than blood culture. Additionally, T2 Biosystems team members will conduct live demonstrations of the T2Candida test being run on its T2Dx instrument throughout exhibit hall hours. Please visit the T2 Bio booth, #732, at the ASM (News - Alert) exhibition hall to learn more about T2MR and T2Candida. For further information on the T2Candida Symposium, please contact [email protected]. T2Candida is for research use only. Not for use in diagnostic procedures. About Sepsis & Candidemia Sepsis is a potentially life-threatening illness caused by the body's severe reaction to infection by bacteria, fungi, viruses or parasites. It is one of the top 10 leading causes of death in the United States, and each hour of delayed treatment increases the mortality of these patients by 8%. Candida is a fungal pathogen known to cause sepsis, and it is associated with approximately 100,000 cases of candidemia in the U.S. annually, making it the fourth-leading cause of hospital-acquired infections. Currently, candidemia has a 40% mortality rate, which can be reduced to 11% with early identification of the specific species. Current detection methods rely on blood culture, a process that can take two to five days before identifying a Candida infection. The T2MR® platform is able to detect species-specific Candida directly from whole blood without the limits experienced with optical detection technology, even at low copy numbers, and provide results in approximately three hours. About T2 Biosystems T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR®, the Company's proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company's products detect molecular, hemostasis or immunodiagnostic targets directly from unpurified clinical samples in hospitals, labs and physicians' offices. For more information, please visit www.t2biosystems.com. |
